Search Result

Results for "

LPA

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apolipoprotein (3) Apoptosis (3) Autophagy (6) Biochemical Assay Reagents (4) Calcium Channel (7) Caspase (1) Cyclophilin (1) Drug Isomer (1) Endogenous Metabolite (5) G Protein-coupled Receptor Kinase (GRK) (1) HIV (4) Isotope-Labeled Compounds (3) LDLR (1) Liposome (1) LPL Receptor (47) MDM-2/p53 (1) Mitosis (1) Phosphodiesterase (PDE) (10) PKA (6) PKC (6) PPAR (1) Ras (1) Reactive Oxygen Species (ROS) (1) Reference Standards (2) ROCK (8) Small Interfering RNA (siRNA) (2) TGF-beta/Smad (1) TRP Channel (1) YAP (2)
By Research Areas:	Cancer (29) Cardiovascular Disease (15) Endocrinology (2) Infection (3) Inflammation/Immunology (22) Metabolic Disease (4) Neurological Disease (18)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Phospholipids (6) Human Pre-designed siRNA Sets (1) siRNA drugs (1) siRNAs (2)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Inhibitory Antibodies

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-18075

LPA2 antagonist 1 3 Publications Verification	LPL Receptor	Cancer
LPA2 antagonist 1 is a *LPA2* antagonist with an IC₅₀ of 17 nM.

HY-113973

LPA2 antagonist 2	LPL Receptor	Cancer
LPA2 antagonist 2 (H2L 5226501) is a selective *LPA₂* antagonist with an IC₅₀ of 28.3 nM and a K_i of 21.1 nM. LPA2 antagonist 2 is >480-fold more selective than LPA₃ (IC₅₀ of 13.85 μM) .

HY-W127502

1-Hexadecyl lysophosphatidic acid 1-Hexadecyl LPA; 1-Palmityl LPA; LPA O-16:0	Biochemical Assay Reagents	Others
1-Hexadecyl lysophosphatidic acid is an ether analog of lysophosphatidic acid (LPA) containing a hexadecyl group in the sn-1 position. LPA binds to five different G protein-coupled receptors and mediates a variety of biological responses, including cell proliferation, smooth muscle contraction, platelet aggregation, neurite contraction, and cell motility.

HY-151392

LPA5 antagonist 2	LPL Receptor	Neurological Disease Inflammation/Immunology
LPA5 antagonist 2 (compound 65) is a high aqueous solubility *LPA5* (lysophosphatidic acid receptor 5) antagonist. LPA5 antagonist 2 significantly attenuates nociceptive hypersensitivity and it can be used for the research of inflammatory and neuropathic pains .

HY-151391

LPA5 antagonist 1	Biochemical Assay Reagents	Neurological Disease
LPA5 antagonist 1 (Compound 66) is a potent and selective lysophosphatidic acid receptor 5 (LPA5) antagonist (IC₅₀=32 nM). LPA5 antagonist 1 shows high brain permeability and anti-nociceptive activity. LPA5 antagonist 1 can be used in inflammatory and neuropathic pain research . LPA5 antagonist 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-18076

LPA1 receptor antagonist 1	LPL Receptor	Infection Inflammation/Immunology
LPA1 receptor antagonist 1 is a highly selective Lysophosphatidic Acid receptor-1 *(LPA1)* antagonist with an IC₅₀ of 25 nM.

HY-160173

LPA receptor antagonist-1	LPL Receptor	Others
LPA receptor antagonist-1 (example 52) is an antagonist of lysophosphatidic acid (LPA) receptor. LPA receptor antagonist-1 can be used for kinds of studies .

HY-173325

LPA2 antagonist 6	LPL Receptor	Cardiovascular Disease
LPA2 antagonist 6 (example 2) is an antagonist of Lp(a). LPA2 antagonist 6 inhibits Lp(a) formation with an IC₅₀ value of 2.33 nM. LPA2 antagonist 6 can be used in the research of cardiovascular disease .

HY-160616

LPA5 antagonist 3	LPL Receptor	Cardiovascular Disease Neurological Disease
LPA5 antagonist 3 (Example 74) is a lysophosphatidic acid receptor 5 (LPA5) antagonist, with an IC₅₀ of 170 nM. LPA5 antagonist 3 can be used for the research of pain disorders and atherosclerosis .

HY-173324

LPA2 antagonist 5	LPL Receptor	Others
LPA2 antagonist 5 (EX1) is a *LPA2* antagonist, with an IC₅₀ of 4.05 nM .

HY-RS07745

LPA Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
LPA Human Pre-designed siRNA Set A contains three designed siRNAs for LPA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LPA Human Pre-designed siRNA Set A LPA Human Pre-designed siRNA Set A

HY-171906

1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA 1-Arachidonoyl-sn-glycerol 3-phosphate; 1-Arachidonoyl LPA; LPA (20:4)	LPL Receptor	Inflammation/Immunology
1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA is a phospholipid containing arachidonic acid at the sn-1 position. It is a precursor to 1-arachidonoyl glycerol (1-Monoarachidin; HY-130567) . 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA binds to the LPA2/EDG4 receptor with an EC50 value of approximately 10 nM . It prevents TNF-α and IL-6 secretion in wild-type but not Lpa2-/- dendritic cells stimulated by LPS . It also decreases differentiation of HT-29 human colon carcinoma cells to goblet cells in the presence of sodium butyrate .

HY-138453

ACT-1016-0707 LPA1 receptor antagonist 2	LPL Receptor	Inflammation/Immunology
ACT-1016-0707 (Compound 49) is an orally active and selective *LPA1* receptor antagonist. ACT-1016-0707 can be used for the research of fibrotic diseases .

HY-171906A

1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA sodium 1-Arachidonoyl-sn-glycerol 3-phosphate sodium; 1-Arachidonoyl LPA sodium; LPA (20:4) sodium	LPL Receptor	Cancer
1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) (1-Arachidonoyl-sn-glycerol 3-phosphate (sodium)) is a phospholipid with arachifonic acid at the sn-1 position. 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) binds to the *LPA₂/EDG4* receptor (EC₅₀ of 10 nM). 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) can be found in rat brain as 37% of the arachidoinic acid-containing lysophosphatidic acid species. 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) is the precursor to 1-arachidonoyl glycerol. 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) can prevent TNF-α and IL-6 secretion in wild type LPS-stimulated dendritic cells. 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) reduces differentiation of HT-29 colon carcinoma cells into goblet cells when sodium butyrate is present .

HY-P991310

Lpathomab LT3015; LT-3000	LPL Receptor	Neurological Disease Cancer
Lpathomab (LT3015; LT-3000) is a human IgG1 monoclonal antibody (mAb) targeting *LPA. Lpathomab reduces the release of IL-8 and IL-6 cytokines in SKOV3 cells and blocks LPA*-triggered tumor cell migration. Lpathomab reduces neovascularization in Matrigel plug and CNV models. Lpathomab inhibits brain injury in the CCI mouse model. Lpathomab can be used in the study of brain injury, ovarian cancer, diabetic neuropathy, and spinal cord injury. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-173322

Lp(a)-IN-8	LPL Receptor
Lp(a)-IN-8 (compound 15) is an Lp(a) inhibitor. Lp(a) is a causal risk factor for atherosclerotic cardiovascular disease (ASCVD) .

HY-171464

Lp(a)-IN-5	Apolipoprotein	Cardiovascular Disease
Lp(a)-IN-5 (Compound A) is an orally active lipoprotein (a) (Lp(a)) inhibitor. Lp(a)-IN-5 inhibits the assembly of Apo(a) and ApoB proteins with an IC₅₀ value of 0.41 nM. Lp(a)-IN-5 is promising for research of diseases related to elevated plasma Lp(a) levels, such as cardiovascular diseases .

HY-171464A

Lp(a)-IN-5 hydrochloride	Apolipoprotein	Cardiovascular Disease
Lp(a)-IN-5 (Compound A) hydrochloride is an orally active lipoprotein (a) (Lp(a)) inhibitor. Lp(a)-IN-5 hydrochloride inhibits the assembly of Apo(a) and ApoB proteins with an IC₅₀ value of 0.41 nM. Lp(a)-IN-5 hydrochloride is promising for research of diseases related to elevated plasma Lp(a) levels, such as cardiovascular diseases .

HY-171465

Lp(a)-IN-6	Others	Cardiovascular Disease
Lp(a)-IN-6 (Compound 6) is a lipoprotein(a) (Lp(a)) inhibitor, with an IC₅₀ of <0.314 nM. Lp(a)-IN-6 can be used for the research of cardiovascular disease (CVD) .

HY-173323

Lp(a)-IN-7	Apolipoprotein	Cardiovascular Disease
Lp(a)-IN-7 (example 1) is a lipoprotein (a) (Lp(a)) formation inhibitor with an IC₅₀ of 2.51 nM in conditioned media containing apolipoprotein B (apoB) and apolipoprotein(a). Lp(a)-IN-7 can be used for the study of cardiovascular disease .

HY-107615

*TC LPA5 4*	LPL Receptor	Cancer
TC LPA5 4 is a LPA₅ (GPR92)-specific non-lipid antagonist. TC LPA5 4 inhibits LPA-induced aggregation of isolated human platelet (LPA₅-RH7777 cell line) with an IC₅₀ of 800 nM. TC LPA5 4 displays selectivity for LPA₅ over 80 other screened agent targets . TC LPA5 4 inhibits cell proliferation and migration of thyroid cancer cells .

HY-146945S

*Arachidonoyl LPA-d5*	Isotope-Labeled Compounds	Others
Arachidonoyl LPA-d₅ is deuterium labeled Arachidonoyl LPA.

HY-146955S

*Linoleoyl LPA-d5*	Isotope-Labeled Compounds	Others
Linoleoyl LPA-d₅ is deuterium labeled Linoleoyl LPA.

HY-146956S

*Oleoyl LPA-d5*	Isotope-Labeled Compounds	Others
Oleoyl LPA-d₅ is deuterium labeled Oleoyl LPA.

HY-107614

1-Oleoyl lysophosphatidic acid sodium 1 Publications Verification 1-Oleoyl-sn-glycero-3-phosphate sodium; 1-Oleoyl-LPA sodium	LPL Receptor Mitosis	Neurological Disease
1-Oleoyl lysophosphatidic acid (1-Oleoyl-sn-glycero-3-phosphate) sodium, a potent bioactive phospholipid, is a LPA receptor activator. 1-Oleoyl lysophosphatidic acid sodium can promote mitosis by inducing DNA synthesis. 1-Oleoyl lysophosphatidic acid sodium is also involved in normal and pathological emotional responses, including anxiety and depression .

HY-157693

C18:1 Cyclic LPA	Endogenous Metabolite	Cancer
C18:1 Cyclic LPA is a naturally occurring analog of the growth factor-like phospholipid mediator, lysophosphatidic acid (LPA), characterized by the formation of a 5-membered ring between its sn-2 hydroxy group and the sn-3 phosphate. This unique structure allows C18:1 Cyclic LPA to influence a variety of cellular functions, such as inhibiting cell cycle progression, promoting the formation of stress fibers, curtailing tumor cell invasiveness and metastasis, and modulating the differentiation and survival of neuronal cells. Notably, many of these cellular effects elicited by C18:1 Cyclic LPA appear to counter those induced by LPA, despite the activation of seemingly similar receptor populations.

HY-15706

H2L 5765834	LPL Receptor	Cardiovascular Disease
H2L 5765834 is an antagonist of lysophosphatidic acid receptors LPA₁, *LPA₃, and LPA₅, with IC₅₀*s of 94, 752, and 463 nM respectively .

HY-W923661

1-Octadecyl lysophosphatidic acid PA(O-18:0/0:0); 1-Oleyl LPA; 1-Octadecyl LPA	LPL Receptor	Others
1-Octadecyl lysophosphatidic acid (compound 10) is a GPR92 receptor (LPA5) activator with potential flavoring effects .

HY-103267A

S32826	Phosphodiesterase (PDE)	Inflammation/Immunology
S32826 is a potent autotaxin inhibitor, with an IC₅₀ of 8.8 nM. S32826 shows similar inhibitory effects at various autotaxin isoforms (α, β and γ). S32826 inhibits LPA release from adipocytes .

HY-120797

CRT0273750 IOA-289	LPL Receptor	Cancer
CRT0273750 is an autotaxin (ATX) inhibitor and modulates LPA levels in plasm (IC₅₀ = 0.014 μM). CRT0273750 can be used in ATX/LPA-dependent models of cancer .

HY-103267

S32826 disodium	Phosphodiesterase (PDE)	Inflammation/Immunology
S32826 disodium is a potent autotaxin inhibitor, with an IC₅₀ of 8.8 nM. S32826 disodium shows similar inhibitory effects at various autotaxin isoforms (α, β and γ). S32826 disodium inhibits LPA release from adipocytes .

HY-128127

NAEPA	LPL Receptor	Others
NAEPA, a phosphate-mimetic derivative, is a lysophosphatidic acid *(LPA) receptor* agonist .

HY-137862

1-Oleoyl lysophosphatidic acid 1 Publications Verification 1-Oleoyl-sn-glycero-3-phosphate; 1-Oleoyl-LPA	LPL Receptor	Neurological Disease
1-Oleoyl lysophosphatidic acid (1-Oleoyl-sn-glycero-3-phosphate) is an abundant lysophosphatidic acid (LPA) species with high biological activity due to its strong affinity for the LPA receptors. 1-Oleoyl lysophosphatidic acid is commonly used in most laboratories as a reagent for LPA receptor activation . 1-Oleoyl lysophosphatidic acid increases SRE-driven β-galactosidase activity .

HY-103267R

S32826 disodium (Standard)	Reference Standards Phosphodiesterase (PDE)	Inflammation/Immunology
S32826 (disodium) (Standard) is the analytical standard of S32826 (disodium). This product is intended for research and analytical applications. S32826 disodium is a potent autotaxin inhibitor, with an IC50 of 8.8 nM. S32826 disodium shows similar inhibitory effects at various autotaxin isoforms (α, β and γ). S32826 disodium inhibits LPA release from adipocytes .

HY-124772

BI-2545	Phosphodiesterase (PDE)	Inflammation/Immunology
BI-2545 is a potent autotaxin (ATX) inhibitor that significantly reduces LPA, with IC₅₀s of 2.2 nM and 3.4 nM for human ATX and rat ATX, respectively .

HY-W783254

C18 LPA PA(18:0e/0:0)	G Protein-coupled Receptor Kinase (GRK) Calcium Channel	Cardiovascular Disease Cancer
C18 LPA (PA(18:0e/0:0)) is a water-soluble phospholipid that functions as a signaling molecule, influencing various cellular responses through G protein-coupled receptors (GPCRs). It is known to promote smooth muscle contraction, cytoskeletal rearrangement, and chemotaxis, while also playing a role in neurotransmitter release, cell proliferation, platelet aggregation, and Ca2+ mobilization. Elevated levels of C18 LPA in human plasma are associated with ovarian cancer and atherosclerosis, suggesting its potential as a biomarker for ovarian cancer.

HY-157617

*16:0 Cyclic LPA* ammonium** 1-Palmitoyl-sn-glycero-2,3-cyclic-phosphate ammonium	Biochemical Assay Reagents	Others
16:0 Cyclic LPA (1-Palmitoyl-sn-glycero-2,3-cyclic-phosphate) ammonium is a palmitoyl cyclic phosphatidic acid .

HY-157669

1-Oleoyl-sn-glycero-2,3-cyclic-phosphate ammonium 18:1 Cyclic LPA	Biochemical Assay Reagents	Others
1-Oleoyl-sn-glycero-2,3-cyclic-phosphate ammonium (18:1 Cyclic LPA) is a cyclic phosphatidic acid that can be used for the preparation of liposomes .

HY-173509

ATX inhibitor 27	Phosphodiesterase (PDE) LPL Receptor	Infection Cardiovascular Disease Neurological Disease Cancer
ATX inhibitor 27 (Compound 31) is an ATX inhibitor. The IC₅₀ values of ATX inhibitor 27 against human autotaxin (hATX) and lysophosphatidylcholine (LPC) are 13 nM and 23 nM, respectively. ATX inhibitor 27 reduces LPA levels in vivo by inhibiting ATX enzyme. ATX inhibitor 27 can be used in the study of ATX-LPA-related diseases such as inflammation, neurodegenerative diseases and cancer .

HY-160003

PPARγ agonist 9	PPAR	Metabolic Disease
PPARγ agonist 9 is an agonist of PPARγ. PPARγ agonist 9 is the analogue of lysophosphatidic acid with an EC₅₀ more than 10 μM for LPA₃ receptor .

HY-137862A

(Rac)-1-Oleoyl lysophosphatidic acid (Rac)-1-Oleoyl-sn-glycero-3-phosphate; (Rac)-1-Oleoyl-LPA	LPL Receptor Drug Isomer	Neurological Disease
(Rac)-1-Oleoyl lysophosphatidic acid is an isomer of 1-Oleoyl lysophosphatidic acid sodium (HY-107614). 1-Oleoyl lysophosphatidic acid sodium is a bioactive lipid that can activate the *LPA* receptors .

HY-174267S

ATX-IN-2	Phosphodiesterase (PDE)	Inflammation/Immunology
ATX-IN-2 (Compound 25) is an orally active and potent ATX inhibitor with an IC₅₀ value of 3.27 nM. ATX-IN-2 reduces lysophosphatidic acid (LPA) secretion. ATX-IN-2 is promising for research of ATX-mediated diseases, such as inflammation, pulmonary fibrosis .

HY-16039

AM095 5+ Cited Publications	LPL Receptor	Inflammation/Immunology
AM095 is a selective *LPA₁* receptor antagonist. The IC₅₀ for AM095 antagonism of LPA-induced calcium flux of human or mouse LPA₁-transfected CHO cells is 0.025 and 0.023 μM, respectively.

HY-15277

AM966 15+ Cited Publications	LPL Receptor	Inflammation/Immunology
AM966 is a high affinity, selective, oral *LPA₁*-antagonist, inhibits LPA-stimulated intracellular calcium release (IC₅₀=17 nM).

HY-114379

AS2717638 1 Publications Verification	LPL Receptor	Neurological Disease Inflammation/Immunology
AS2717638 is a highly selective, brain-penetrant and orally active lysophosphatidic acid receptor 5 (LPA5) antagonist with an IC₅₀ value of 38 nM. AS2717638 is highly selective and shows no significant antagonistic activity against other LPA receptors (LPA1, LPA2, and LPA3). AS2717638 can be used in the research of pain and neuroinflammation-related diseases .

HY-129808

VPC12249	LPL Receptor	Cardiovascular Disease Cancer
VPC12249 is a competitive dual *LPA1/LPA3* antagonist with K_i values of 137nM and 428 nM, respectively. VPC12249 inhibits calcium mobilization in HEK293T cells with a K_i value of ~130 nM. VPC12249 is promising for research of ovarian cancer and hypertensive diseases .

HY-120478

ASP6432	LPL Receptor	Infection
ASP6432 is a potent and selective type 1 lysophosphatidic acid receptor (LPA1) antagonist with IC₅₀s of 11 nM and 30 nM for human LPA1 and rat LPA1, respectively .

HY-18641

Ki16198	LPL Receptor	Cancer
Ki16198 is a potent and orally active LPA receptor antagonist, the methyl ester of Ki16425 (HY-13285). Ki16198 inhibits LPA₁ and LPA₃-induced inositol phosphate production with?K_i?values of 0.34 μM and 0.93 μM, respectively. Ki16198 is effective for pancreatic cancer tumorigenesis and metastasis in vivo .

HY-167862A

UCM-05194 ammonium	LPL Receptor	Neurological Disease
UCM-05194 (ammonium) is a lysophosphatidic acid receptor 1 (LPA1) agonist. UCM-05194 (ammonium) induces calcium mobilization in LPA1-expressing RH7777 cells (EC₅₀ = 0.24 µM). UCM-05194 (ammonium) induces neurite retraction and migration in LPA1-overexpressing B103 rat neuroblastoma cells. UCM-05194 (ammonium) attenuates acetic acid-induced writhing and hind paw mechanical hypersensitivity in mice .

HY-114380

Radioprotectin-1	LPL Receptor	Others
Radioprotectin-1 is a potent and specific nonlipid agonist of lysophosphatidic acid receptor 2 (LPA₂), with an EC₅₀ value of 25 nM for murine LPA₂ subtype .

Cat. No.	Product Name	Type

HY-107614G

1-Oleoyl lysophosphatidic acid sodium (GMP)

1-Oleoyl-sn-glycero-3-phosphate sodium (GMP); 1-Oleoyl-LPA sodium (GMP)

Fluorescent Dye

1-Oleoyl lysophosphatidic acid sodium (GMP) is a GMP-grade 1-Oleoyl lysophosphatidic acid sodium (HY-107614) that can be used as an auxiliary reagent in cell therapy. 1-Oleoyl lysophosphatidic acid sodium can stimulate neuronal differentiation in neural progenitor cells from mice or rats, and it also promotes the differentiation of human adipose-derived mesenchymal stem cells into myofibroblast-like cells in vitro by activating the autocrine TGF-β1-Smad signaling pathway .

Cat. No.	Product Name	Type

HY-W127502

1-Hexadecyl lysophosphatidic acid 1-Hexadecyl LPA; 1-Palmityl LPA; LPA O-16:0	Cell Assay Reagents
1-Hexadecyl lysophosphatidic acid is an ether analog of lysophosphatidic acid (LPA) containing a hexadecyl group in the sn-1 position. LPA binds to five different G protein-coupled receptors and mediates a variety of biological responses, including cell proliferation, smooth muscle contraction, platelet aggregation, neurite contraction, and cell motility.

HY-157617

*16:0 Cyclic LPA* ammonium** 1-Palmitoyl-sn-glycero-2,3-cyclic-phosphate ammonium	Drug Delivery
16:0 Cyclic LPA (1-Palmitoyl-sn-glycero-2,3-cyclic-phosphate) ammonium is a palmitoyl cyclic phosphatidic acid .

HY-157669

1-Oleoyl-sn-glycero-2,3-cyclic-phosphate ammonium 18:1 Cyclic LPA	Drug Delivery
1-Oleoyl-sn-glycero-2,3-cyclic-phosphate ammonium (18:1 Cyclic LPA) is a cyclic phosphatidic acid that can be used for the preparation of liposomes .

HY-107614G

1-Oleoyl lysophosphatidic acid sodium (GMP)

1-Oleoyl-sn-glycero-3-phosphate sodium (GMP); 1-Oleoyl-LPA sodium (GMP)

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Area

HY-P991310

Lpathomab LT3015; LT-3000	LPL Receptor	Neurological Disease Cancer
Lpathomab (LT3015; LT-3000) is a human IgG1 monoclonal antibody (mAb) targeting *LPA. Lpathomab reduces the release of IL-8 and IL-6 cytokines in SKOV3 cells and blocks LPA*-triggered tumor cell migration. Lpathomab reduces neovascularization in Matrigel plug and CNV models. Lpathomab inhibits brain injury in the CCI mouse model. Lpathomab can be used in the study of brain injury, ovarian cancer, diabetic neuropathy, and spinal cord injury. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

Cat. No.	Product Name	Chemical Structure

HY-146945S

*Arachidonoyl LPA-d5*
Arachidonoyl LPA-d₅ is deuterium labeled Arachidonoyl LPA.

HY-146955S

*Linoleoyl LPA-d5*
Linoleoyl LPA-d₅ is deuterium labeled Linoleoyl LPA.

HY-146956S

*Oleoyl LPA-d5*
Oleoyl LPA-d₅ is deuterium labeled Oleoyl LPA.

HY-174267S

ATX-IN-2
ATX-IN-2 (Compound 25) is an orally active and potent ATX inhibitor with an IC₅₀ value of 3.27 nM. ATX-IN-2 reduces lysophosphatidic acid (LPA) secretion. ATX-IN-2 is promising for research of ATX-mediated diseases, such as inflammation, pulmonary fibrosis .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P84010

	LPA Antibody (YA3707) LP; AK38; APOA	IHC-P, ICC/IF, ELISA	Human
	LPA Antibody (YA3707) is a mouse-derived and non-conjugated IgG1 antibody, targeting to LPA. It can be applicated for IHC-P, ICC/IF, ELISA assays, in the background of human.

HY-P82987

	ApoA Antibody (YA2732) LPA; Apolipoprotein(a; Apo(a); Lp(a)	WB	Human
	ApoA Antibody (YA2732) is a non-conjugated IgG antibody, targeting ApoA, with a predicted molecular weight of 227 kDa (observed band size: 501 kDa). ApoA Antibody (YA2732) can be used for WB experiment in human background.

HY-P83630

	EDG2 Antibody (YA3375) Lysophosphatidic acid receptor 1; LPA receptor 1; LPA-1; Lysophosphatidic acid receptor Edg-2; LPAR1; EDG2; LPA1	WB, IHC-P, IP	Human
	EDG2 Antibody (YA3375) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3375), targeting EDG2, with a predicted molecular weight of 41 kDa (observed band size: 41 kDa). EDG2 Antibody (YA3375) can be used for WB, IHC-P, IP experiment in human background.

HY-P85037

	ApoA Antibody (YA4729) LPA; Apolipoprotein; a; Apo; a; Lp; a;	WB, IHC-P, ICC/IF, ELISA	Human
	ApoA Antibody (YA4729) is a mouse-derived and non-conjugated monoclonal antibody, targeting to ApoA. It can be applicated for WB, IHC-P, ICC/IF, ELISA assays, in the background of human.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-151391

LPA5 antagonist 1		Alkynes
LPA5 antagonist 1 (Compound 66) is a potent and selective lysophosphatidic acid receptor 5 (LPA5) antagonist (IC₅₀=32 nM). LPA5 antagonist 1 shows high brain permeability and anti-nociceptive activity. LPA5 antagonist 1 can be used in inflammatory and neuropathic pain research . LPA5 antagonist 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Cat. No.	Product Name		Classification

HY-153492A

Olpasiran sodium AMG 890 sodium; ARC-LPA sodium		siRNAs siRNA drugs
Olpasiran sodium is a small interfering RNA that reduces lipoprotein(a) synthesis in the liver.

HY-RS07745

LPA Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
LPA Human Pre-designed siRNA Set A contains three designed siRNAs for LPA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-157693

C18:1 Cyclic LPA		Phospholipids
C18:1 Cyclic LPA is a naturally occurring analog of the growth factor-like phospholipid mediator, lysophosphatidic acid (LPA), characterized by the formation of a 5-membered ring between its sn-2 hydroxy group and the sn-3 phosphate. This unique structure allows C18:1 Cyclic LPA to influence a variety of cellular functions, such as inhibiting cell cycle progression, promoting the formation of stress fibers, curtailing tumor cell invasiveness and metastasis, and modulating the differentiation and survival of neuronal cells. Notably, many of these cellular effects elicited by C18:1 Cyclic LPA appear to counter those induced by LPA, despite the activation of seemingly similar receptor populations.

HY-157725

C18:1 LPA		Phospholipids
C18:1 LPA, a bioactive lipid derived from membrane phospholipids, plays a crucial role in various cellular processes and is found in blood plasma, where it is linked to neurological disorders, inflammation, and cancer.

HY-W783254

C18 LPA PA(18:0e/0:0)		Phospholipids
C18 LPA (PA(18:0e/0:0)) is a water-soluble phospholipid that functions as a signaling molecule, influencing various cellular responses through G protein-coupled receptors (GPCRs). It is known to promote smooth muscle contraction, cytoskeletal rearrangement, and chemotaxis, while also playing a role in neurotransmitter release, cell proliferation, platelet aggregation, and Ca2+ mobilization. Elevated levels of C18 LPA in human plasma are associated with ovarian cancer and atherosclerosis, suggesting its potential as a biomarker for ovarian cancer.

HY-157617

*16:0 Cyclic LPA* ammonium** 1-Palmitoyl-sn-glycero-2,3-cyclic-phosphate ammonium		Phospholipids
16:0 Cyclic LPA (1-Palmitoyl-sn-glycero-2,3-cyclic-phosphate) ammonium is a palmitoyl cyclic phosphatidic acid .

HY-157669

1-Oleoyl-sn-glycero-2,3-cyclic-phosphate ammonium 18:1 Cyclic LPA		Phospholipids
1-Oleoyl-sn-glycero-2,3-cyclic-phosphate ammonium (18:1 Cyclic LPA) is a cyclic phosphatidic acid that can be used for the preparation of liposomes .

HY-145486

1-Arachidonoyl-sn-glycerol 3-phosphate ammonium 20:4 Lyso PA		Phospholipids
1-Arachidonoyl-sn-glycerol 3-phosphate ammonium (20:4 Lyso PA) is a phospholipid and an LPA derived from arachidonic acid. The concentration of 1-Arachidonoyl-sn-glycerol 3-phosphate ammonium in plasma is significantly correlated with the age of onset of cocaine use and the duration of abstinence. 1-Arachidonoyl-sn-glycerol 3-phosphate ammonium can be used in the research of biomarkers for cocaine use disorder (CUD) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: